130 related articles for article (PubMed ID: 35030629)
1. Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease.
DePriest BP; Li H; Bidgoli A; Onstad L; Couriel D; Lee SJ; Paczesny S
Blood Adv; 2022 May; 6(10):2981-2986. PubMed ID: 35030629
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
[TBL] [Abstract][Full Text] [Related]
3. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
Ferrara JL; Harris AC; Greenson JK; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Huber E; Landfried K; Akashi K; Vander Lugt M; Reddy P; Chin A; Zhang Q; Hanash S; Paczesny S
Blood; 2011 Dec; 118(25):6702-8. PubMed ID: 21979939
[TBL] [Abstract][Full Text] [Related]
4. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
[TBL] [Abstract][Full Text] [Related]
5. [Correlation of the level of Reg3α protein in plasma with gastrointestinal acute graft-versus-host disease].
Cai CS; Chen GH; Sun AN; Qiao M; Liu HW; Chen F; Wang Y; Qiu HY; Han Y; Ma X; Tang XW; Jin ZM; Fu CC; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):785-90. PubMed ID: 24989295
[TBL] [Abstract][Full Text] [Related]
6. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2019; 10():2338. PubMed ID: 31649665
[TBL] [Abstract][Full Text] [Related]
7. Biomarker Panel for Chronic Graft-Versus-Host Disease.
Yu J; Storer BE; Kushekhar K; Abu Zaid M; Zhang Q; Gafken PR; Ogata Y; Martin PJ; Flowers ME; Hansen JA; Arora M; Cutler C; Jagasia M; Pidala J; Hamilton BK; Chen GL; Pusic I; Lee SJ; Paczesny S
J Clin Oncol; 2016 Aug; 34(22):2583-90. PubMed ID: 27217465
[TBL] [Abstract][Full Text] [Related]
8. Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use.
Weber D; Weber M; Meedt E; Ghimire S; Wolff D; Edinger M; Poeck H; Hiergeist A; Gessner A; Ayuk F; Roesler W; Wölfl M; Kraus S; Zeiser R; Bertrand H; Bader P; Ullrich E; Eder M; Gleich S; Young R; Herr W; Levine JE; Ferrara JLM; Holler E
Blood Adv; 2023 Apr; 7(7):1326-1335. PubMed ID: 36350750
[TBL] [Abstract][Full Text] [Related]
9. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification.
Etra A; Gergoudis S; Morales G; Spyrou N; Shah J; Kowalyk S; Ayuk F; Baez J; Chanswangphuwana C; Chen YB; Choe H; DeFilipp Z; Gandhi I; Hexner E; Hogan WJ; Holler E; Kapoor U; Kitko CL; Kraus S; Lin JY; Al Malki M; Merli P; Pawarode A; Pulsipher MA; Qayed M; Reshef R; Rösler W; Schechter T; Van Hyfte G; Weber D; Wölfl M; Young R; Özbek U; Ferrara JLM; Levine JE
Blood Adv; 2022 Jun; 6(12):3707-3715. PubMed ID: 35443021
[TBL] [Abstract][Full Text] [Related]
10. The association between acute graft-versus-host disease and antimicrobial peptide expression in the gastrointestinal tract after allogeneic stem cell transplantation.
Weber D; Frauenschläger K; Ghimire S; Peter K; Panzer I; Hiergeist A; Weber M; Kutny D; Wolff D; Grube M; Huber E; Oefner P; Gessner A; Hehlgans T; Herr W; Holler E
PLoS One; 2017; 12(9):e0185265. PubMed ID: 28934349
[TBL] [Abstract][Full Text] [Related]
11. Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease.
Zhao D; Kim YH; Jeong S; Greenson JK; Chaudhry MS; Hoepting M; Anderson ER; van den Brink MR; Peled JU; Gomes AL; Slingerland AE; Donovan MJ; Harris AC; Levine JE; Ozbek U; Hooper LV; Stappenbeck TS; Ver Heul A; Liu TC; Reddy P; Ferrara JL
J Clin Invest; 2018 Nov; 128(11):4970-4979. PubMed ID: 30106382
[TBL] [Abstract][Full Text] [Related]
12. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
13. Have we made progress in the treatment of GVHD?
Harris AC; Levine JE; Ferrara JL
Best Pract Res Clin Haematol; 2012 Dec; 25(4):473-8. PubMed ID: 23200544
[TBL] [Abstract][Full Text] [Related]
14. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y
Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932
[TBL] [Abstract][Full Text] [Related]
15. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
Hartwell MJ; Özbek U; Holler E; Renteria AS; Major-Monfried H; Reddy P; Aziz M; Hogan WJ; Ayuk F; Efebera YA; Hexner EO; Bunworasate U; Qayed M; Ordemann R; Wölfl M; Mielke S; Pawarode A; Chen YB; Devine S; Harris AC; Jagasia M; Kitko CL; Litzow MR; Kröger N; Locatelli F; Morales G; Nakamura R; Reshef R; Rösler W; Weber D; Wudhikarn K; Yanik GA; Levine JE; Ferrara JL
JCI Insight; 2017 Feb; 2(3):e89798. PubMed ID: 28194439
[No Abstract] [Full Text] [Related]
16. Plasma biomarkers of lower gastrointestinal and liver acute GVHD.
Harris AC; Ferrara JL; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Landfried K; Akashi K; Vander Lugt M; Couriel DR; Reddy P; Paczesny S
Blood; 2012 Mar; 119(12):2960-3. PubMed ID: 22286196
[TBL] [Abstract][Full Text] [Related]
17. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
19. Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
Hotta M; Satake A; Yoshimura H; Fujita S; Katayama Y; Ota S; Hanamoto H; Oyake T; Ito S; Okada M; Nakanishi T; Ito T; Ishii K; Nomura S
Transplant Cell Ther; 2021 Aug; 27(8):660.e1-660.e8. PubMed ID: 33989832
[TBL] [Abstract][Full Text] [Related]
20. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE
Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
